topotecan has been researched along with nutlin-3a in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ayrault, O; Roussel, MF; Zindy, F | 1 |
Dalgard, CL; deNiro, JE; Gonzalez, M; O'Brien, JM | 1 |
Dudgeon, DD; Giuliano, KA; Johnston, PA; Lazo, JS; Shinde, SN; Shun, TY; Strock, CJ; Taylor, DL | 1 |
de Lange, J; Jager, MJ; Jochemsen, AG; Lodder, K; Ly, LV; Teunisse, AF; Verlaan-de Vries, M | 1 |
Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M | 1 |
5 other study(ies) available for topotecan and nutlin-3a
Article | Year |
---|---|
[TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Transformation, Neoplastic; Cellular Senescence; Cyclin D; Cyclin-Dependent Kinases; Cyclins; DNA Damage; Eye Neoplasms; Genes, p16; Genes, p53; Genes, Retinoblastoma; Humans; Imidazoles; Mice; Models, Biological; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma; Retinoblastoma Protein; Topotecan; Tumor Suppressor Protein p14ARF; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2007 |
Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Survival; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MicroRNAs; Piperazines; Retinal Neoplasms; Retinoblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Topics: Antineoplastic Agents; Biosensing Techniques; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 2; Ellipticines; Genes, p53; High-Throughput Screening Assays; Humans; Imidazoles; Mitoxantrone; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Small Molecule Libraries; Spectrometry, Fluorescence; Topotecan; Tumor Suppressor Protein p53 | 2010 |
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Synergism; Furans; Humans; Hypoxia; Imidazoles; Melanoma; Melanoma, Experimental; Mice; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Topotecan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uveal Neoplasms | 2012 |
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea | 2016 |